fashion -WSS

fashion

author：leisure time 2025-08-27 16:47:29 - browse：2457

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Healthy food access boosts outcomes in two studies

entertainment

WSS

Medicare’s new pay boost for primary care is angering specialists

Asbestos ban is immediate, but health effects will linger for decades

Steward Health Care expansion into Malta flopped

Cancer diagnosis changes perspective doctor, former hospital CEO

Surgeons perform first xenotransplant using CRISPR'd pig kidney

FDA reorg will put new emphasis on investigations, sources say

entertainment

fashion

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Weight loss drugs should be covered by insurers, AMA says

Dobbs anniversary: the lost opportunity of abortion as health care

Ventyx halts psoriasis drug development after lackluster trial results

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: Illumina, CRISPR, Regeneron

Medical leaders decry Supreme Court decision on affirmative action

This gene therapy has record $4.25 million price. It's saved children.

Supreme Court strikes down use of affirmative action

CRISPR technology availability, affordability needs to be expanded

entertainment

Pfizer, Moderna say biotech, pharma drug development is a sprint

First transplant of an entire human eye performed

Weight loss drugs should be covered by insurers, AMA says

First transplant of an entire human eye performed

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Publishing genetic code of viruses could cause disaster

explore

focus

entertainment

focus